following a full submission:
osimertinib (Tagrisso®) is accepted for use within NHSScotland.
Indication under review: treatment of adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy.
In a double-blind, phase III study, osimertinib compared with placebo, after platinum-based chemoradiotherapy, significantly improved progression-free survival in adults with locally advanced, unresectable, stage III NSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Medicine details
- Medicine name:
- osimertinib (Tagrisso)
- SMC ID:
- SMC2815
- Indication:
For treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum‑based chemoradiation therapy.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 April 2026